Literature DB >> 15331695

Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.

Sang-Moo Kang1, Lizheng Guo, Qizhi Yao, Ioanna Skountzou, Richard W Compans.   

Abstract

Intranasal immunization with inactivated influenza virus vaccine can provide protective immunity, whereas many other antigens are less effective when used for mucosal immunization. To determine whether influenza virus could enhance immune responses to an antigen coadministered to a mucosal surface, we studied the intranasal immunization of mice with a mixture of simian-human immunodeficiency virus (SHIV) virus-like particles (VLPs) and inactivated influenza virus. Compared to mice immunized with SHIV VLPs alone, mice coimmunized with SHIV VLPs and inactivated influenza virus showed significant increases in serum immunoglobulin G (IgG) and mucosal IgA antibodies specific to the human immunodeficiency virus envelope protein, neutralizing activities, numbers of gamma interferon- and interleukin 4-secreting lymphocytes, and cytotoxic-T-lymphocyte activities. The levels of enhancement of immune response by coimmunization with inactivated influenza virus were equivalent to those induced by inclusion of immunostimulatory CpG oligodeoxynucleotides (CpG DNA). We also observed that SHIV VLPs bind to influenza virus virions, forming mixed aggregates. These results indicate that inactivated influenza virus can play a role as a mucosal adjuvant to coadministered antigens. Copyright 2004 American Society for Microbiology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331695      PMCID: PMC514968          DOI: 10.1128/JVI.78.18.9624-9632.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection.

Authors:  T M Moran; H Park; A Fernandez-Sesma; J L Schulman
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

2.  CpG DNA as mucosal adjuvant.

Authors:  M J McCluskie; H L Davis
Journal:  Vaccine       Date:  1999-09       Impact factor: 3.641

3.  Immunostimulatory DNA is a potent mucosal adjuvant.

Authors:  A A Horner; A Ronaghy; P M Cheng; M D Nguyen; H J Cho; D Broide; E Raz
Journal:  Cell Immunol       Date:  1998-11-25       Impact factor: 4.868

4.  High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160.

Authors:  H Hocini; L Bélec; S Iscaki; B Garin; J Pillot; P Becquart; M Bomsel
Journal:  AIDS Res Hum Retroviruses       Date:  1997-09-20       Impact factor: 2.205

5.  Identification of multiple simian immunodeficiency virus (SIV)-specific CTL epitopes in sooty mangabeys with natural and experimentally acquired SIV infection.

Authors:  A Kaur; J Yang; D Hempel; L Gritz; G P Mazzara; H McClure; R P Johnson
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

6.  Purification and characterization of simian immunodeficiency virus (SIVmac) envelope glycoprotein gp130 from virus-infected cells.

Authors:  D H Jones; B W McBride; M A Roff; V Maloney; G H Farrar
Journal:  Vaccine       Date:  1994       Impact factor: 3.641

7.  Induction of cytotoxic and helper T cell responses by modified simian immunodeficiency virus hypervariable epitope constructs.

Authors:  D Meyer; J V Torres
Journal:  Viral Immunol       Date:  1999       Impact factor: 2.257

8.  A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes.

Authors:  M Lagranderie; N Winter; A M Balazuc; B Gicquel; M Gheorghiu
Journal:  AIDS Res Hum Retroviruses       Date:  1998-12-20       Impact factor: 2.205

9.  Production and characterization of simian--human immunodeficiency virus-like particles.

Authors:  Q Yao; F M Kuhlmann; R Eller; R W Compans; C Chen
Journal:  AIDS Res Hum Retroviruses       Date:  2000-02-10       Impact factor: 2.205

10.  Costimulation by B7 modulates specificity of cytotoxic T lymphocytes: a missing link that explains some bystander T cell activation.

Authors:  P Zheng; Y Liu
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

View more
  16 in total

1.  Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways.

Authors:  William A Langley; Konrad C Bradley; Zhu-Nan Li; Mary Ellen Smith; Matthias J Schnell; David A Steinhauer
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

Authors:  Fu-Shi Quan; Chunzi Huang; Richard W Compans; Sang-Moo Kang
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

Review 3.  Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Expert Opin Biol Ther       Date:  2010-08       Impact factor: 4.388

4.  Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease.

Authors:  Yu-Na Lee; Hye Suk Hwang; Min-Chul Kim; Young-Tae Lee; Min-Kyoung Cho; Young-Man Kwon; Jong Seok Lee; Richard K Plemper; Sang-Moo Kang
Journal:  Virology       Date:  2014-12-30       Impact factor: 3.616

5.  Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins.

Authors:  Fu-Shi Quan; Gangadhara Sailaja; Ioanna Skountzou; Chunzi Huang; Andrei Vzorov; Richard W Compans; Sang-Moo Kang
Journal:  Vaccine       Date:  2007-02-15       Impact factor: 3.641

6.  Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.

Authors:  Yu-Na Lee; Hye Suk Hwang; Min-Chul Kim; Young-Tae Lee; Jong Seok Lee; Martin L Moore; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2014-12-13       Impact factor: 5.970

7.  Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge.

Authors:  Maria del P Martin; Shaguna Seth; Dimitrios G Koutsonanos; Joshy Jacob; Richard W Compans; Ioanna Skountzou
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

8.  Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine.

Authors:  Ioanna Skountzou; Maria del Pilar Martin; Baozhong Wang; Ling Ye; Dimitrios Koutsonanos; Will Weldon; Joshy Jacob; Richard W Compans
Journal:  Vaccine       Date:  2009-08-03       Impact factor: 3.641

9.  Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.

Authors:  Yu-Na Lee; Min-Chul Kim; Young-Tae Lee; Yu-Jin Kim; Jongsang Lee; Cheol Kim; Suk-Hoon Ha; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2015-08-04       Impact factor: 5.970

Review 10.  Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.

Authors:  Shujing Wang; Huiqin Liu; Xinyi Zhang; Feng Qian
Journal:  Protein Cell       Date:  2015-05-06       Impact factor: 14.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.